Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Medipharm Labs Corp T.LABS

Alternate Symbol(s):  MEDIF

MediPharm Labs Corp. is a Canada-based full-service pharmaceutical company. The Company specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products. Through its wholesale and white label platforms, the Company formulates, develops (including through sensory testing), processes, packages and distributes cannabis extracts and advanced cannabinoid-based products to domestic and international markets. It also provides GMP flower sourcing, packaging, and distribution services for select international clients. In addition, it cultivates cannabis to sell as dried flower, pre-roll and other cannabis products for the adult use and medical markets. It also sells metered dose inhalers and aerosol sublingual sprays. Through Harvest Medicine, it provides clinic services to Canadian patients requiring medical cannabis education and prescriptions.


TSX:LABS - Post by User

Comment by alleyesonmeon Mar 15, 2024 11:52am
96 Views
Post# 35935022

RE:Continued progress ... shortened path to profitability

RE:Continued progress ... shortened path to profitabilityWhen you consider at the beginning of q4.........new products launched in the tightly regulated Australian market, (replenishment happened much sooner than expected according to Keith's twitter)....pre rolls in germany, two new supply deals in the U.K, growing Canadian sales according to headset, including the number 1oil consecutively in Ontario (nighttime formula) , the elimination of royalties to shelter with prerolls accounting for 30%of the 5 billion market in Canada...the commencement of 3m annualized savings beginning at the beginning of q4...and the award of 30m shares to insiders and management for performance...this leads me to believe we could see the best quarter in years...I like to silence from the Corp...no fluff....Revenue and Cost Synergies Realizable in the Near-Term:(1)(2)(3)(4) Using forecasts derived collaboratively by both management teams, along with revenue and cost synergy estimates, the pro-forma Combined Company aims to find positive EBITDA(6) synergies to the magnitude of between $7M to $9Mon an annualized basis, and could reach positive EBITDA and cash flow in the first half of 2024.
<< Previous
Bullboard Posts
Next >>